

CONCOMITANT TREATMENT WITH ATEZOLIZUMAB AND ENZALUTAMIDE FOR METASTASTIC NON-SMALL-CELL LUNG CANCER AND METASTASTIC PROSTATE CANCER: A CASE REPORT

Melgarejo Ortuño A¹, Bautista Sanz MP¹, Sánchez de Torre A², Bernal Hertfelder E², Apezteguía Fernández CA¹, Amor García MA¹, De Cáceres Velasco C¹, Moreno Díaz R¹.


¹Servicio de Farmacia. Hospital Universitario Infanta Cristina. Parla, Spain

²Servicio de Oncología Médica. Hospital Universitario Infanta Cristina. Parla, Spain

BACKGROUND AND IMPORTANCE

No cases have been reported in clinical practice with experience in the management of patients with lung and prostate cancer under concomitant treatment with atezolizumab and enzalutamide.

AIM AND OBJECTIVE




MATERIALS AND METHODS

This was a **descriptive, retrospective clinical case**. The data (diagnostic tests, therapy and clinical course) were obtained by review of electronic medical records.

Adherence was evaluate using medication possession ratio (MPR).

RESULTS



No cases have been reported in the literature, but there is one phase III trial, Imbassador250, which at least reports concomitant administration of the two drugs for prostate cancer. Given the **favourable safety data** and the efficacy data reported for both treatments for their corresponding indications, enzalutamide is initiated while treatment with atezolizumab is maintained. **No toxicity** from the treatments has been reported. The patient has maintained both treatments to the present day, maintaining clinical response for both tumours. The patient has shown 100% adherence to oral and intravenous treatment.

CONCLUSION AND RELEVANCE



This is the **first case report** with evidence of efficacy of concomitant treatment with **atezolizumab** for lung cancer and **enzalutamide** for prostate cancer, with no additional toxicity.

It is important to report these cases in real clinical practice, because these conditions will not be present in clinical trials.

